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Background: In addition to treating acute promyelocytic leukemia, arsenic trioxide (ATO) suppresses other solid
tumors, including chondrosarcoma. However, the effects of ATO on metastasis in chondrosarcoma cells, and the
underlying molecular mechanisms remain unclear.
Methods: The effects of ATO on the migratory and invasive capacities of chondrosarcoma cells were investigated
by Wound healing, Transwell and EMT assays. The expression of miR-125b in human chondrosarcoma tissues and
cell lines was detected by real-time PCR analysis. Bisulfite sequencing analysis (BSP) was used to detect the effects
of ATO on the expression of miR-125b. The gain-of-function and loss-of-function experiments were performed on
chondrosarcoma cell lines to investigate the effects of miR-125b on chondrosarcoma invasion, and to determine
whether signal transducer and activator of transcription 3(Stat3) mediates these effects. Dual-luciferase reporter
assay was used to identify whether Stat3 is a direct target of miR-125b.
Results: MiR-125b was significantly downregulated in human metastatic chondrosarcoma tissues and cell lines but
not in non-metastatic chondrosarcoma tissues. ATO up-regulates the expression of miR-125b by the demethylation
of DNA. ATO induces MET and attenuates the invasive capacities of chondrosarcoma cells through miR-125b. Stat3
was verified as a direct target of miR-125b, which is involved in ATO regulating EMT-associated traits.
Conclusions: These findings, for the first time, provides evidence that the miR-125b-mediated inhibition of Stat3 is
involved in the ATO-induced attenuation of metastasis in chondrosarcoma cells.
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Chondrosarcoma is the second most common primary
bone tumor. Current practices for the treatment of chon-
drosarcoma include wide-margin surgical resection and
chemotherapy and are less than satisfactory because of high
recurrence rates and metastasis [1–3]. The mechanisms
underlying metastasis and recurrence remain obscure. A
continued search for molecular markers that predict metas-
tasis and the recurrence of chondrosarcoma is essential.
Emerging evidence suggests that the epithelial-
mesenchymal transition (EMT) contributes to tumor
metastasis and recurrence in chondrosarcoma and other
tumors [4, 5]. Chondrosarcoma cells undergoing EMT
triggered by various stimuli might acquire altered traits
involving chemoresistance, migration, and stemness
[6, 7]. Although several lines of evidence have demon-
strated the significance of the EMT in chondrosarcoma
progression, the molecular mechanisms that regulate
EMT remain unclear.
Accumulating evidence suggests that microRNAs
(miRNAs) play important roles in regulating EMT in
cancer cells [5, 8, 9]. MiRNAs, which are small, noncoding
RNA molecules of 20–24 nucleotides, have the capacity to
inhibit at the post-transcriptional and/or transcriptional
level mainly by targeting the 3’-untranslated regions of
mRNAs [10, 11].
It has been reported that almost every type of cancer,
including chondrosarcoma, displays a specific profile of
aberrantly expressed miRNAs that might be used as po-
tential biomarkers or as therapeutic targets [12–18].
MiR-125b is a frequently downregulated miRNA in vari-
ous types of tumors, including colorectal cancer and
liver cancer [19, 20]. It has been reported that miR-125b is
downregulated in human osteosarcoma cells [21]. How-
ever, there is little known about the effects of miR-125b in
chondrosarcoma.
Arsenic trioxide (ATO) is an FDA-approved drug
employed for the standard therapy of patients with acute
promyelocytic leukemia (APL) [22]. In addition, the
anti-cancer effects of ATO have been observed in other
solid tumors, such as liver, breast, prostate and osteosar-
coma [23, 24].
Some studies show that ATO treatment attenuates the
EMT and invasive capacities of cancer cells [25, 26]. It
has been reported that ATO could induce demethylation
of DNA and cause up-regulation of certain genes and
microRNAs (miRNAs) [27, 28].
Herein, we report that ATO attenuates the migratory and
invasive capacities of chondrosarcoma cells in vitro and
in vivo. In human chondrosarcoma cells, ATO up-regulates
the expression of miR-125b by the demethylation of DNA,
which induces the MET process in vitro and in vivo.
Furthermore, we demonstrated that miR-125b inhibited
the EMT process in chondrosarcoma cells by targetingsignal transducer and activator of transcription 3 (Stat3);
constitutive activation of Stat3 is a key player in tumor
angiogenesis and metastasis.
We believe that the data from our study could provide a
new mechanism underlying the anti-migration/invasion
effect of arsenic trioxide on human chondrosarcoma.
Methods
Human tissue specimen
Fourteen chondrosarcoma tissues from the patients with
metastases and non-metastases, 7 samples from the adja-
cent normal tissues (located > 3 cm away from the tumor)
were collected under the protocols approved by the ethics
committee of Peking University People’s Hospital. In-
formed consents (written in the light of the ethical guide-
lines) were obtained from all the patients. The clinical
characteristics of these patients were shown in Table 1.
Fresh tissues were stored in liquid nitrogen before RNA
extraction. The paraffin-embedded pathological specimens
from 10 patients with chondrosarcoma and adjacent non-
tumor tissues were obtained from the Department of
Pathology and the Musculoskeletal Tumor Center, Peking
University People’s Hospital (Beijing, China).
Cell culture and reagents
The human articular chondrocyte cell line HC-a (Sciencell,
Carlsbad, CA, USA) was maintained in DMEM supple-
mented with 15 % fetal bovine serum, plus antibiotics.
SW1353 cells were obtained from American Type Culture
Collection (ATCC, Manassas, VA) and were maintained in
L-15 medium (Gibco, Grand Island, NY). OUMS-27 cells,
HCS-2/8 cells and JJ012 cells were kindly gifted from Dr. J
Block (Rush Medical College, Chicago, IL, USA) and were
cultured in Dulbecco Modified Eagle Medium (Hyclone,
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(Gibco, Grand Island, NY) at 37 °C in a humidified atmos-
phere with 5 % CO2.
ATO was purchased from Sigma Chemical Co. (St. Louis,
MO, USA). The following antibodies were used in the
experiments: anti-p-STAT3, anti-STAT3, anti-E-cadherin,
anti-Vimentin, anti-Bax and anti-GAPDH were from
Cell Signaling Technology (Beverly, MA, USA). anti-
N-cadherin, anti-Slug, anti-MMP9 were from Abcam
(USA). STAT3 siRNA were purchased from Suzhou
GenePharma (Suzhou, China). Lipofectamin 3000 was
bought from Origene (Rockville, MD, USA).
Western blot analysis
Equal amounts of proteins collected from different kinds
of cell lysates were loaded on 10–15 % SDS-PAGE gels
using a NuPAGE system (Invitrogen) and then transferred
onto PVDF membranes as previously described [22].
Immunohistochemistry
Paraffin sections were reacted with rabbit polyclonal
anti-p-Stat3, anti-vimentin, anti-N-cadherin and anti-E-
cadherin antibodies (1:200 dilution). Sections stained with
nonimmune rabbit serum (1:200 dilution) in phosphate-
buffered saline (PBS) instead of primary antibody served
as negative controls. Cells exhibiting positive staining on
cell membranes and in the cytoplasm and nucleus were
counted in at least 10 representative fields (×400magnifi-
cation) and the mean percentage of positive cells was
calculated. Immunostaining was assessed by two inde-
pendent pathologists blinded to clinical characteristics
and outcomes.
Wound healing assay
A total of 2 × 105 OUMS-27, HCS-2/8 and SW1353 cells
were seeded into a 24-well plate. The tumor cells were
grown to confluence 24 h later. An artificial wound was
introduced with a P10 pipette tip in each well. The data
of the wounded area were recorded at 0 h and 24 h with
a microscope (Olympus Corp). The entire assay was re-
peated three times.
Transwell assay
OUMS-27 and SW1353 cells were harvested, washed,
suspended with RPMI1640 (GIBCO, Life Technologies,
11965–092) or L-15 medium (Gibco, Grand Island, NY),
and seeded into the upper chambers of transwell inserts
(8 μ m pore size; Corning) with or without 1.5 μM ATO
in the migration assay. The upper chambers were coated
with Matrigel (BD Bioscience, 354234) before the inocu-
lation of the cancer cells and ATO in the invasion assay.
The lower compartments were filled with RPMI1640
or L-15 medium supplemented with 5 % FBS (fetal bo-
vine serum). The cells in the upper chamber wereremoved with a swab after incubation for 12 h in the mi-
gration assay or 24 h in the invasion assay. The cells that
migrated to the lower layer and attached to the mem-
brane were stained with crystal violet and were counted
in five fields per well under a microscope. The whole
assay was repeated three times.
Epithelial-mesenchymal transition (EMT) induction
OUMS-27 and HCS-2/8 cells were cultured to attach in
complete medium overnight. Then, the cells were main-
tained in either medium alone or medium supplemented
with 2.5 ng/ml TGF-β 1 (R&D Systems, Minneapolis,
MN) with or without 1.5 μM 5 ATO in a humidified 5 %
CO2 incubator at 37 °C. The morphologic photos of the
cells were taken seven days after the incubation. The ex-
periments were repeated three times.
Quantitative RT-PCR (qRT-PCR)
The miRNAs were isolated from chondrosarcoma tissues
or cell lines using an RNeasy/miRNeasy Mini kit (Qiagen,
Limburg, The Netherlands) according to the manufac-
turer’s instructions. Total RNA was isolated using the
TRIzol reagent (Invitrogen). The cDNAs were synthesized
using a RevertAidTM First Strand cDNA Synthesis kit
(Fermentas, Vilnius, Lithuania), and real-time quantitative
PCR was carried out using the SYBR-Green PCR Master
Mix (Applied Biosystems, Foster City, CA, USA) on a
7900 Real-Time PCR System (Applied Biosystems).
The primers used in this study were as follows: STAT3-
F, 5′- CCCCATACCTGAAGACCAAG-3′and STAT3-R,
5′- GGACTCAAACTGCCCTCCT-3′; E-cadherin, CDH-
1-F, 5′- TGCTCACATTTCCCAACTC-3′ and CDH-1-R,
5′-TCTGTCACCTTCAGCCATC-3’; N-cadherin, CDH-
2-F, 5′- CTGACAATGACCCCACAGC-3′and CDH-2-R,
5′-TCCTGCTCACCACCACTACTT-3′; miR-125b, 5′-
AATCCCTGAGACCCTAACTTGTGA-3′.
MiR-125b target prediction and cell transfection
Three online programs, PicTar (http://pictar.mdc-berlin.de),
and Tarbase (http://diana.cslab.ece.ntua.gr/tarbase), were
used in combination with previous reports for predicting
the target genes of miR-125b.
Anti-miR-125b and anti-con lentivirus vector con-
struction, lentivirus packaging, and cell transfection have
been previously described [20]. SiStat3, miR-125b-mimic,
miR-125b-inhibitor, and miRNA-NC (negative control)
were synthesized by Suzhou GenePharma. Cells were
transiently transfected using Lipofectamine 2000 re-
agent (Invitrogen) for 12 h, according to the manufac-
turer’s protocol.
Luciferase reporter assay
The Stat3 3′-untranslated region (3′UTR) containing
the wild type or mutated miR-125b binding sequences
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China), and were cloned into the pmirGLO luciferase re-
porter vector (Promega, Madison, WI, USA). HEK293
cells were transfected with the wild type/mutant Stat3
luciferase reporter vector and miR-125b mimic/miR-
Control using Lipofectamine 2000. Firefly and Renilla
luciferase activities were measured using the Dual-
Luciferase Reporter Assay System (Promega). Results
were expressed as the firefly luciferase activity normalized
to Renilla luciferase activity.
Bisulfite sequencing analysis (BSP)
The methylation status of miR-125b promoter was de-
termined by BSP. miR-125b DNA was extracted using a
DNA kit (Qiagen 51306, Germany), and 2 μg of DNA
was subjected to bisulfite conversion using an EpiTect
Bisulfite Kit (59104, Qiagen, Germany) according to the
manufacturer’s instructions. The transformed DNA was
then PCR-amplified using the TaKaRa rTaq Kit (R001B,
TaKaRa, Dalian, China). The PCR amplification products
were sequenced by Invitrogen Corporation, Shanghai.
The primers for miR-125b, miR-125b-F, 5’-TTTATT
TTTAGTTTGATGAGGAAAG -3’, and miR-1125b-R,
5’-CACCAAACTATCATTTAATAAACAC -3’ were used
for qRT-PCR.
Generation of xenografts
Six-week-old BALB/c female athymic nude mice (Vitalriver,
Beijing, China) were subcutaneously injected in the
right flank with cells (2 × 106 in 0.1 ml PBS). After
chondrosarcoma cells developed palpable tumors, the mice
were randomly divided into two groups and administered
intraperitoneally with DMSO or ATO at a dose of 2 mg/kg
every other day for 30 days. The volume of xenograftsFig. 1 Expression of miR-125b in human chondrosarcoma tissues and cells
the patients with metastases, non-metastases and the adjacent normal tiss
expression in human chondrosarcoma cell lines (HCS-2/8, OUMS-27, SW135
(HC-a). **P < 0.01 compared with HC-awas measured every five days (tumor volume = (length ×
width2)/2). The mice were sacrificed after 30 days. Tumor
samples were processed for routine IHC.
The tumor metastatic ability of HCS-2/8 cells (5 ×
106cells) was observed following cell injection intraven-
ously into the tail vein. Four weeks later, the mice were
randomly divided into two groups and administered in-
traperitoneally with DMSO or ATO at a dose of 2 mg/
kg every other day for 30 days (n = 6 per group); the
mice were then sacrificed, and the number of metastatic
nodules on the lung surface was counted. Metastatic
lungs were fixed with 4 % paraformaldehyde before de-
hydration and paraffin embedding. Paraffin sections were
stained with hematoxylin and eosin according to stand-
ard protocols.
Statistical analysis
The influence of ATO on the migration, invasion, EMT
and tumor formation of chondrosarcoma cells was ana-
lyzed by Student t test or One-Way ANOVA. In all stat-
istical analyses, statistical significance in the two-sided
test was indicated with P values of 0.05 or less, and a P
value less than 0.01 was remarkably significant.
Results
MiR-125b expression was downregulated in human
metastatic chondrosarcoma tissues and cells
The expression level of miR-125b was quantified by real-
time quantitative reverse transcription PCR in primary
chondrosarcoma tissues and chondrosarcoma cell lines.
The results showed that there is no significant difference
between the adjacent normal tissues and the non-
metastatic chondrosarcoma tissues in the expression
level of miR-125b. However, miR-125b expression was. a Relative expression of miR-125b in chondrosarcoma tissues from
ues. **P < 0.01 compared with normal. b Fold change of miR-125b
3, and JJ012) and the normal human articular chondrocyte cell line
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than that in adjacent normal tissues and non-metastatic
chondrosarcoma tissues (Fig. 1a, **P < 0.01). Compared
with the human articular chondrocyte cell line HC-a,
the expression levels of miR-125b were significantly
downregulated in the chondrosarcoma cell lines, includ-
ing HCS-2/8, OUMS-27, SW1353, and JJ012 (Fig. 1b,
**P < 0.01).Fig. 2 ATO Attenuates the Migratory and Invasive Capacities of Chondrosa
OUMS-27 or SW1353 cells at concentrations of 0.5, 1.0 or 1.5 μM. b ATO re
Migration rates were calculated by the healing area/wound area after 24 h
with transwell analysis. d ATO significantly inhibits the invasion of chondroATO attenuates the migratory and invasive capacities of
chondrosarcoma cells
ATO did not appreciably affect the vitality of HCS-2/8,
OUMS-27 or SW1353 cells at concentrations of 0.5, 1.0
or 1.5 μM (Fig. 2a).
HCS-2/8, OUMS-27 and SW1353 cells displayed high
migration and invasion capacities, although ATO attenu-
ated migration, as determined by wound healing assays,rcoma Cells. a ATO did not appreciably affect the vitality of HCS-2/8,
duces the migration of chondrosarcoma cells in wound-healing assays.
. c ATO significantly suppresses the migration of chondrosarcoma cells
sarcoma cells with Boyden chamber analysis. (*P < 0.05, **P < 0.01)
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was selected as the maximum for further investigations.
Furthermore, as determined with transwell assays, ATO
decreased the invasive capacity of HCS-2/8, OUMS-27
and SW1353 cells (Fig. 2c and d). These results show that
ATO could effectively attenuate the migratory and inva-
sive capacities of human chondrosarcoma cells.
ATO suppresses the epithelial-mesenchymal transition of
chondrosarcoma cells
The epithelial-mesenchymal transition (EMT) is a crit-
ical process for epithelial cells to harbor mesenchymal
properties and is closely involved in cancer invasion and
metastasis [18]. To evaluate the effect of ATO on this
process, we induced EMT of chondrosarcoma cells with
TGF-β1 [18, 19] and observed that the cell lines showed
a mesenchymal appearance, which was fibroblast-like
(Fig. 3a). When treated with ATO, however, the chondro-
sarcoma cell lines maintained their epithelial appearance,
indicating that ATO efficiently blocked the EMT induced
by TGF-β1. Moreover, ATO impaired the expression ofFig. 3 ATO suppresses the epithelial-mesenchymal transition of chondrosa
chondrosarcoma cells. b Protein expression levels of Vimentin, N-cadherin
TGF-β1 and ATO treatmentmesenchymal cell markers, including N-cadherin, Vimentin
and slug; however, there was increased epithelial cell
marker E-cadherin (Fig. 3b).
ATO up-regulates the expression of miR-125b by the
demethylation of DNA in HCS-2/8 and OUMS-27 cells
As demonstrated herein, in ATO-treated HCS-2/8,
OUMS-27 and SW1353 cells, there was increased ex-
pression of miR-125b. The qRT-PCR results for miR-
125b expression in the experiments are shown (Fig. 4a).
Biotransformation of arsenic results in a deficiency of
methyl donors, reducing DNA methylation, which ac-
tivates a series of target genes [29]. We hypothesized
that ATO up-regulated the expression of miR-125b by
demethylation.
BSP was used to evaluate the promoter methylation
status of miR-125b.
HCS-2/8 and OUMS-27 cells were treated with 0 or
1.5 μM of ATO. The methylation ratio of the 7 CpG loci
became 57.1 % (4/7) and 42.8 % (4/7) from 100.0 %,
respectively (Fig. 4b).rcoma cells. a ATO reverses the EMT transition induced by TGF-β1 in
and E-cadherin were determined in HCS-2/8 and OUMS-27 cells with
Fig. 4 ATO Up-Regulates the Expression of miR-125b by Demethylation of DNA in Chondrosarcoma Cells. a HCS-2/8, OUMS-27 and SW1353 cells
were exposed to 1.5 μM ATO for 24 h. qRT-PCR analyses of miR-125b levels (mean ± SD, n = 3). **P < 0.01 compared with control cells. b A pathway
showing the demethylation effects induced by As3+. As3+MT (As3+ methyltransferase), MMA, monomethylarsinic acid; DMA, dimethylarsinic
acid. c BSP shows that the miR-125b methylation ratio of the 7 CpG loci became 57.1 % (4/7) and 42.8 % (4/7) from 100.0 % in HCS-2/8
and OUMS-27 cells, respectively
Bao et al. Journal of Experimental & Clinical Cancer Research  (2016) 35:129 Page 7 of 13ATO induces MET and attenuates the invasive capacities
of chondrosarcoma cells through miR-125b
The present data show that the over-expression of miR-
125b enhanced the expression of E-cadherin but de-
creased the expression of N-cadherin, Slug and MMP9 in
HCS-2/8 cells (Fig. 5a–c). After HCS-2/8 cells were trans-
fected with anti-con or anti-miR-125b for 12 h, the cells
were exposed to 0.0 or 1.5 μM ATO for 48 h. The ATO-
induced increased expression of E-cadherin and decreased
expression of N-cadherin were impaired by knockdown of
miR-125b (Fig. 5 d–f ).
ATO attenuated the invasive capacity, as determined
by transwell assays, in chondrosarcoma cells; however,
the knockdown of miR-125b reduced these effects in
chondrosarcoma cells (Fig. 6).
These results indicate that in HCS-2/8, OUMS-27 and
SW1353 cells, miR-125b is involved in the ATO-induced
MET and the inhibition of invasive capacity.
Stat3 is a novel direct target of miR-125b, which is
involved in ATO regulating EMT-associated traits
We explored the molecular mechanisms by which miR-
125b affects ATO-mediated EMT suppression.Bioinformatics analysis using PicTar (http://pictar.mdc-
berlin.de) indicated the potential binding sites in the
3’UTR of Sat3 (Fig. 6g). Previous studies suggested that
Stat3 is a significant inducer of EMT by the transcrip-
tional activation of slug and twist1 [30].
We examined the effects of ATO on the activation of
Stat3 in chondrosarcoma cells. As shown in Fig. 7a,
ATO decreased the activation of Stat3 in a time and
dose-dependent manner in HCS-2/8 cells.
We detected a direct binding of miR-125b to the 3’UTR
of Stat3 with a dual-luciferase reporter assay (Fig. 7b and c)
and observed significant downregulation of Stat3 in miR-
125b-overexpressing chondrosarcoma cells (Fig. 7d). We
also found that miR-125b knockdown up-regulated Stat3
expression and rescued siRNA-mediated Stat3 suppression
in chondrosarcoma cells (Fig. 7e and f). The knockdown of
miR-125b blocked the ATO-induced inactivation of Stat3
in HCS-2/8 and OUMS-27 cells (Fig. 7g).
ATO up-regulates the expression of miR-125b and inhibits
metastasis in vivo
Five days after HCS-2/8 cells were injected subcutane-
ously into the right armpit of nude BALB/c mice, the
Fig. 5 ATO induces MET and attenuates the invasive capacities of chondrosarcoma cells through miR-125b. HCS-2/8 cells were transfected with a
con-mimic or miR-125b-mimic for 12 h. a qRT-PCR analyses of miR-125b and CDH-1 levels (mean ± SD, n = 3). b Western blot analyses and (c)
relative protein levels of E-cadherin, N-cadherin, Slug and MMP9 (mean ± SD, n = 3). **P < 0.01 and *P < 0.05 compared with control cells or cells
transfected with con-mimic. After HCS-2/8 cells were transfected by anti-con or anti-miR-125b for 12 h, they were exposed to 1.5 μM ATO for
48 h. d qRT-PCR analyses of miR-125b and CDH-1 levels (mean ± SD, n = 3); e Western blot analyses and (f) relative protein levels of E-cadherin
and N-cadherin (mean ± SD, n = 3)
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ively. Sterile saline or ATO (2 mg/kg BW) was adminis-
tered intraperitoneally in 100 mL of sterile saline every
other day for another 4 weeks. At that time, the tumors
were removed and evaluated by qRT-PCR, immunohis-
tochemistry and Western blot. In line with the in vitro
data, ATO increased the E-cadherin expression and de-
creased the p-Stat3, vimentin and N-cadherin expression
in tumors formed by chondrosarcoma cells (Fig. 8a–c).
ATO also markedly attenuated the metastatic potential
of chondrosarcoma cells, as evidenced by the decreased
lung metastasis occurrence. After HCS-2/8 cells were
injected intravenously into the tail vein at 2 weeks, the
mice were intraperitoneally administered ATO (0 or
2 mg/kg BW) in 100 mL of sterile saline every other day
for another 30 days. The ATO-treated mice displayed
statistically significantly lower numbers of lung metasta-
ses than the control group. After hematoxylin and eosin
staining, an observation of the lungs showed that fewer
lung metastatic nodes were observed in the mice treated
with ATO (Fig. 8d).To confirm the function of miR-125b in ATO-induced
suppression of EMT, we established stable anti-miR-125b
and anti-con HCS-2/8 cell lines. After the two stable
cell lines were injected intravenously into the tail vein
at 2-weeks, the mice were treated as previously de-
scribed. Fewer lung metastatic nodules were observed
in the anti-con group compared with the anti-miR-
125b group (Fig. 8e).
Together, these findings strongly indicate that ATO in-
hibits EMT and invasive capacity through the miR-125b/
Stat3 axis in chondrosarcoma cells.
Discussion
Chondrosarcoma is the second most frequent type of
primary bone cancer following osteosarcoma [1–3]. At
present, surgical resection remains the only effective
means of treating chondrosarcoma; however, the prog-
nosis of chondrosarcoma remains poor because of high
resistance to conventional chemo- and radiotherapy
and metastasis. For this reason, anti-metastasis therapy
Fig. 6 After OUMS-27 and SW1353 cells were transfected by anti-con or anti-miR-125b for 12 h, they were exposed to 1.5 μM ATO for
48 h. Results of transwell assays and relative levels of cell invasive capacity (mean ± SD, n = 3) in OUMS-27 (a and b) and SW1353
(c and d) cells. **P < 0.01 compared with medium control cells; #P < 0.05 and ##P < 0.01 compared with anti-con-transfected cells
treated by ATO
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sarcoma [29].
EMT, consisting in the transdifferentiation of epithelial
cells into mesenchymal cells, is closely related to the
regulation of immune and chemo resistance, the cancer
stem cell phenotype and metastasis in cancer [30, 31].
Accumulating evidence suggests that Snail1, Twist1, Slug
and Zeb1 are crucial to EMT, which reflected in repres-
sion of epithelial markers like E-cadherin and upregula-
tion of mesenchymal markers like vimentin, N-cadherin
and MMPs [32].
ATO is effective in treating acute promyelocytic
leukemia, and its therapeutic effects on solid tumors arebeing evaluated [33]. In vivo studies, a dose range from
0.5 to 5.0 mg/kg of ATO and the i.p. route were used in
the mouse model to determine the effects of arsenic tri-
oxide on the EMT, metastasis, invasion, and angiogen-
esis of several cancers [34–37].
Our previous study showed that ATO treatment led to
the promotion of G2/M arrest and the induction of
apoptosis and autophagy in chondrosarcoma cells [22].
However, little is known regarding the effects of ATO on
the EMT and metastasis of human chondrosarcoma and
the underlying molecular mechanisms.
Herein, we exposed chondrosarcoma cells to 2 μM
ATO and found that ATO inhibites EMT and attenuates
Fig. 7 Stat3 is a novel direct target of miR-125b, which is involved in ATO regulating EMT-Associated traits in chondrosarcoma cells.
a ATO inhibits Stat3 in a time and dose-dependent manner. b The Stat3 3′UTR region containing the wild type or mutant binding site
for miR-125b. c Dual-luciferase reporter assay of miR-125b with 3’UTR fragments (wild type or mutant) of human Stat3 (NM_003150.3).
Western blotting analysis of Stat3 expression in miR-125b-overexpressing cells (d) and in cells post-miR-125b inhibitor transfection (e)
or with cotransfection with si-Stat3 (f). g Knockdown of miR-125b blocked the ATO-induced inactivation of Stat3 in HCS-2/8 and
OUMS-27 cells
Bao et al. Journal of Experimental & Clinical Cancer Research  (2016) 35:129 Page 10 of 13the migration and invasion of chondrosarcoma cells.
Meanwhile, there was no detectable cytotoxicity of 2 μM
ATO in chondrosarcoma or the human articular chon-
drocyte cell line HC-a. This suggests that arsenic triox-
ide plays a positive effect in inhibiting metastasis in
chondrosarcoma. However, the mechanism about inhib-
ition of EMT and metastasis by ATO is obscure in
chondrosarcoma.
It is reported that miRNAs play significant role in
EMT [38]. MiRNAs are small non-coding RNAs that
regulate gene expression by binding to the 3’-UTR of
the target mRNA and inhibiting translation or targeting
the mRNA for degradation [12]. Almost every type of
cancer, including chondrosarcoma, displays a specific
profile of aberrantly expressed miRNAs [39–48]. MiR-
125b is reported to be a tumor suppressor gene in HCC,
ovarian cancer, bladder cancer, breast cancer and osteo-
sarcoma [19–21]. The roles of miR-125b in chondrosar-
coma and the underlying molecular mechanisms remain
largely uninvestigated.Several studies reveal that ATO affects the tumor cell
growth and metastasis through a complicated process
that includes the regulation of signal pathways, tran-
scriptional factors and microRNA [29, 35, 49].
Herein, in ATO-treated chondrosarcoma cells, for the
first time, we identified that miR-125b exhibited a tumor
suppressor function, which attenuated the EMT and in-
vasive capacities by targeting Stat3, which is activated to
trigger the molecular events in the EMT of various hu-
man tumors [50–54]. Furthermore, our data revealed
that the elevation of miR-125b by ATO was dependent
on the DNA demethylation. This study suggests a prom-
ising therapeutics target in chondrosarcoma and prob-
ably in other types of metastatic malignant tumors.
Conclusions
The present study, for the first time, provides evidence
that the miR-125b-mediated inhibition of Stat3 is in-
volved in the ATO-induced attenuation of metastasis in
chondrosarcoma cells.
Fig. 8 ATO Up-Regulates the Expression of miR-125b and Inhibits Metastasis In Vivo. a Observation of tumors formed by HCS-2/8 cells (left).
qRT-PCR analyses of miR-125b, CDH-1 and CDH-2 levels in xenografts (Right) (mean ± SD, n = 3). **P < 0.01 compared with tumors treated with no
ATO. b Immunohistochemistry analyses of p-Stat3, E-cadherin, N-cadherin and vimentin levels. c Western blot analyses of p-Stat3, E-cadherin,
N-cadherin and vimentin. d Number of metastatic nodules on the surface of the lungs of mice injected with DMSO or ATO is presented.
Representative images and H&E staining of lungs on day 70 after the mice were injected with HCS-2/8 cells (n = 6 per group). e Number
of metastatic nodules on the surface of the lungs of mice formed by stable anti-miR-125b or anti-con HCS-2/8 cells is presented
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